PMC:6218602 / 6383-6932 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6218602","sourcedb":"PMC","sourceid":"6218602","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6218602","text":"Treatment resistance has been most characterized in schizophrenia by how responsive the positive symptom domain is to antipsychotic medications. It is estimated that 70–80% of patients with schizophrenia have a phenotype of psychosis that is responsive to dopamine-blocking treatment (13). However, in over 100 years of treatment history and despite the improvements made to the functional selectivity and potency of antipsychotic medications, 60% of patients continue to fail to achieve symptom improvement after several weeks on drug therapy (14).","tracks":[{"project":"2_test","denotations":[{"id":"30425662-21457676-41865330","span":{"begin":285,"end":287},"obj":"21457676"},{"id":"30425662-8092334-41865331","span":{"begin":545,"end":547},"obj":"8092334"}],"attributes":[{"subj":"30425662-21457676-41865330","pred":"source","obj":"2_test"},{"subj":"30425662-8092334-41865331","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#ec9b93","default":true}]}]}}